About HLK
Scientific Advisory Board

 

Dr. Mark Kontny

Dr. Mark Kontny is a member of Scientific Advisory Board of HLK.  Hi is a C-level executive with broad experience managing the global development, manufacture and supply chain of pharmaceuticals with expertise across Chemistry, Manufacturing & Controls.  He has worked with several multi-national pharmaceutical companies with executive positions include President, Pharmaceutical Development Services & Chief Scientific Officer, Patheon, and Divisional Vice President, Global Pharmaceutical & Analytical Sciences, Abbott Laboratories.  As a strategic business leader, he has the following experience with proven track record:
Managing drug product CMC strategy and execution.
Assessing the pharmaceutical development market & delivering offerings to drive revenue, improve profit margins and significantly enhance operational and organizational effectiveness. 
Leading Operations to deliver numerous new drug/biologic and life cycle management regulatory submissions, approvals and launches on time and on budget.
Transforming organizations through optimization of science, technologies, facilities and efficient operations to build strong service oriented teams and drive a culture focused on quality and continuous improvement across multiple international sites. 
Providing, obtaining and managing outsourcing services.
M & A assessment, due diligence, organizational transitions and integrations.
 


 

 

Professor Dianqing (Dan) Wu, PhD

Professor Wu is the Professor of Pharmacology at the Yale School of Medicine.  His research has been focused on studying signal transduction pathways.  He also is the Adjunct Profess of Department of Genetics and Developmental Biology, University of Connecticut. Prior to his current faculty position, he has held faculty positions at other universities, including University of Connecticut and University of Rochester.  He currently is funded by five NIH grants and has received 24 grants overall from NIH, CT State and different associations.  He is the member of the American Association for the Advancement of Science, member of the American Society of Biochemistry and Molecular Biology and member of the American Society of Cell Biology.  He is the members of the Editorial Board for several journals, including "Current Genomics", "the Journal of Biological Chemistry", "the Journal of Orthopedic Surgery and Research", and "Cell Research".  He is also the Associate Editors for "Prostaglandins and Other Lipid Mediators", and "In Vitro Cellular & Developmental Biology – Animal".  He has been ad hoc reviewers of NIH grant application and numeric prestigious journals, such as Nature, Science, Cell, etc.  He has authored more than 100 papers, 4 patents, and numeric presentations and invited lectures.

 


 

 

Dr. Yijun Cheng

Dr. Yijun Cheng is a medical oncologist/hematologist in private practice in Williamsville, New York. He is a partner in the Department of Oncology of Buffalo Medical Group, PC..

Dr. Cheng earned his medical degree at the Second Military Medical University in Shanghai, China. In addition, he received a PhD in cancer biology at the University of Texas M.D. Anderson Cancer Center. He completed internal medicine and medical oncology/hematology specialty training in University at Buffalo (UB)-affiliated hospitals and the Roswell Park Cancer Institute.
Licensed to practice in the State of New York and State of Pennsylvania, Dr. Cheng is board certified by American Board of Internal Medicine, American Board of Medical Oncology and American Board of Hematology. He is a member of the American College of Physicians, American Society of Clinical Oncology and American Society of Hematology. He has worked with several Pharmaceutical and Biotechnology companies as clinical consultant over the past several years, including Cephalon, Eli Lilly, Amgen and Bayer.

 


 

Tel: +86-755-86007001   Email: info@hlkpharma.com